Abstract:Intestinal inflammatory disorders, such as inflammatory bowel disease, are major contributors to mortality and morbidity in humans and animals worldwide. While some native peptides have great potential as therapeutic agents against intestinal inflammation, potential cytotoxicity, anti-inciting action, and suppression of anti-inflammatory activity may limit their development as anti-inflammatory agents. Peptide hybridization is an effective approach for the design and engineering of novel functional peptides because hybrid peptides combine the advantages and benefits of various native peptides. In the present study, a novel hybrid anti-inflammatory peptide that combines the active center of Cecropin A (C) and the core functional region of LL-37 (L) was designed [C-L peptide; C (1-8)-L (17-30)] through in silico analysis to reduce cytotoxicity and improve the anti-inflammatory activity of the parental peptides. The resulting C-L peptide exhibited lower cytotoxicity than either C or L peptides alone. C-L also exerted a protective effect against lipopolysaccharide (LPS)-induced inflammatory responses in RAW264.7 macrophages and in the intestines of a mouse model. The hybrid peptide exhibited increased anti-inflammatory activity compared to the parental peptides. C-L plays a role in protecting intestinal tissue from damage, LPS-induced weight loss, and leukocyte infiltration. In addition, C-L reduces the expression levels of tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), IL-1β, and interferon-gamma (IFN-γ), as well as reduces cell apoptosis. It also reduced mucosal barrier damage caused by LPS. The anti-inflammatory effects of the hybrid peptide were mainly attributed to its LPS-neutralizing activity and antagonizing the activation of LPS-induced Toll-like receptor 4-myeloid differentiation factor 2 (TLR4/MD2). The peptide also affected the TLR4-(nuclear factor κB) signaling pathway, modulating the inflammatory response upon LPS stimulation. Collectively, these findings suggest that the newly designed peptide, C-L, could be developed into a novel anti-inflammatory agent for animals or humans.

A Hybrid Peptide DEFB-TP5 Expressed in Methylotrophic Yeast Neutralizes LPS with Potent Anti-inflammatory Activities.

Expression and Purification of Hybrid LL-37Tα1 Peptide in Pichia pastoris and Evaluation of Its Immunomodulatory and Anti-inflammatory Activities by LPS Neutralization

A Novel Peptide Ameliorates LPS-Induced Intestinal Inflammation and Mucosal Barrier Damage via Its Antioxidant and Antiendotoxin Effects

In Vitro Impact of Yeast Expressed Hybrid Peptide CATH-2TP5 As a Prophylactic Measure Toward Sepsis and Inflammation.

Yeast Expressed Hybrid Peptide CLP Abridged Pro-Inflammatory Cytokine Levels by Endotoxin Neutralization

Human Beta-Defensin DEFB126 is Capable of Inhibiting LPS-mediated Inflammation

C-Terminal Amination of a Cationic Anti-Inflammatory Peptide Improves Bioavailability and Inhibitory Activity Against LPS-Induced Inflammation

A Highly Efficient Hybrid Peptide Ameliorates Intestinal Inflammation and Mucosal Barrier Damage by Neutralizing Lipopolysaccharides and Antagonizing the Lipopolysaccharide‐receptor Interaction

Design of Hybrid Β-Hairpin Peptides with Enhanced Cell Specificity and Potent Anti-Inflammatory Activity.

Expression and Functional Characterization of a Novel Antimicrobial Peptide: Human Beta-Defensin 118.

Lipopolysaccharide Neutralization by a Novel Peptide Derived from Phosvitin.

Broad-spectrum Hybrid Antimicrobial Peptides Derived from PMAP-23 with Potential LPS Binding Ability.

Expression of Hybrid Peptide EF-1 in Pichia pastoris, Its Purification, and Antimicrobial Characterization

Recombinant expression of a novel antimicrobial peptide consisting of human α-defensin 5 and Mytilus coruscus mytilin-1 in Escherichia coli

The Novel Human Beta-Defensin 114 Regulates Lipopolysaccharide (Lps)-Mediated Inflammation And Protects Sperm From Motility Loss

Design and high-level expression of a hybrid antimicrobial peptide LF15-CA8 in Escherichia coli

A Synthetic MD-2 Mimetic Peptide Attenuates Lipopolysaccharide-Induced Inflammatory Responses in Vivo and in Vitro.

Design and Immunological Evaluation of a Hybrid Peptide As a Potent TLR2 Agonist by Structure-Based Virtual Screening.

Development of a Highly Efficient Hybrid Peptide That Increases Immunomodulatory Activity Via the TLR4-Mediated Nuclear Factor-κB Signaling Pathway

Design and Development of a Novel Peptide for Treating Intestinal Inflammation

The novel human β-defensin 114 regulates lipopolysaccharide (LPS)-mediated inflammation and protects sperm from motility loss.